PVLA — PALVELLA THERAPEUTICS INC NE
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About PALVELLA THERAPEUTICS INC NE (PVLA)
PALVELLA THERAPEUTICS INC NE (PVLA) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $12M. Across recent filings, tracked investors recorded 1 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in PVLA
How many top investors track PVLA
A small number of top investors own this.
PVLA Ownership Composition
How PALVELLA THERAPEUTICS INC NE is held across tracked investor types, based on reported 13F positions.
- Other63.0%
- Hedge Funds37.0%
Tracked investors reporting PVLA
- Izzy EnglanderMar 31, 2026Millennium ManagementShares93.6KValue$11.7M% Portfolio0.00%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares88.2KValue$11M% Portfolio0.01%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares56.5KValue$7M% Portfolio0.00%
Recent activity
- Sold$0(-100.00%)May 15, 2026
- New$275Feb 17, 2026
Frequently asked questions
- How many institutional investors hold PVLA?
- 3 tracked institutional investors disclosed a position in PVLA (PALVELLA THERAPEUTICS INC NE) in their most recent 13F filing.
- Who is the largest institutional holder of PVLA?
- Izzy Englander, Millennium Management, holds the largest disclosed position in PVLA, valued at $12M.
- Did institutional ownership of PVLA increase or decrease?
- Across recent 13F filings, tracked investors recorded 1 new positions, 0 increased, 0 reduced, and 1 fully exited PVLA.
- Where does this PVLA ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.